[1] |
KUMAR V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and Sepsis-associated acute lung injury[J]. Front Immunol, 2020, 11:1722. DOI: 10.3389/fimmu.2020.01722.
|
[2] |
葛均波,徐永健,王辰. 内科学[M]. 9版. 北京:人民卫生出版社,2018:130-131.
|
[3] |
BANAVASI H, NGUYEN P, OSMAN H,et al. Management of ARDS-what works and what does not[J]. Am J Med Sci, 2021, 362(1):13-23. DOI: 10.1016/j.amjms.2020.12.019.
|
[4] |
WANG X Y, LIN F X, GUO L S. TILRR aggravates Sepsis-induced acute lung injury by suppressing the PI3K/Akt pathway[J]. Evid Based Complement Alternat Med, 2022, 2022:7341504. DOI: 10.1155/2022/7341504.
|
[5] |
LIU C, XIAO K, XIE L X. Advances in the use of exosomes for the treatment of ALI/ARDS[J]. Front Immunol, 2022, 13:971189. DOI: 10.3389/fimmu.2022.971189.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
WILLIAMSON PR, ALTMAN DG, BAGLEY H,et al. The COMET Handbook:version 1.0. Trials. 2017 Jun 20; 18(Suppl 3):280. DOI: 10.1186/s13063-017-1978-4.
|
[11] |
|
[12] |
|
[13] |
刘文婷. 参汤对脓毒症致急性呼吸窘迫综合征患者免疫功能的研究[D]. 广州:广州中医药大学,2017.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
刘绛云. 基于"肺合大肠"的大承气汤治疗脓毒症肺损伤的临床及实验研究[D]. 南京:南京中医药大学,2019.
|
[20] |
袁金霞. 针药结合法对脓毒症急性呼吸窘迫综合症患者胃肠功能影响的临床研究[D]. 广州:广州中医药大学,2019.
|
[21] |
|
[22] |
李辉,吴少丽,陈佳杰. 通腑泻下活血法治疗肺热腑实型脓毒症肺损伤的临床研究[J]. 中医药导报, 2020, 26(14):55-59. DOI: 10.1002/jcla.22882.
|
[23] |
|
[24] |
|
[25] |
|
[26] |
吴少丽. 通腑泻下活血法治疗脓毒症肺损伤的临床疗效[J]. 内蒙古中医药,2020,39(10):3-4.
|
[27] |
周敏莹. 针药结合宣肺调肠法对脓毒症ARDS患者呼吸功能影响的临床研究[D]. 广州:广州中医药大学,2020.
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[45] |
|
[46] |
|
[47] |
|
[48] |
ZHANG L, LONG K L, WANG C X,et al. Effects of Fusu mixture (Wen-Shen-Qian-Yang Method) on sepsis-induced acute respiratory distress syndrome[J]. Medicine (Baltimore), 2020, 99(29):e21066. DOI: 10.1097/MD.0000000000021066.
|
[49] |
LI X. Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury[J/OL].[2022-11-12].
|
[50] |
|
[51] |
|
[52] |
VETTER T R, MASCHA E J. Defining the primary outcomes and justifying secondary outcomes of a study:usually,the fewer,the better[J]. Anesth Analg, 2017, 125(2):678-681. DOI: 10.1213/ANE.0000000000002224.
|
[53] |
GORMAN E A, O'KANE C M, MCAULEY D F. Acute respiratory distress syndrome in adults:diagnosis,outcomes,long-term sequelae,and management[J]. Lancet, 2022, 400(10358):1157-1170. DOI: 10.1016/S0140-6736(22)01439-8.
|
[54] |
NUNNA K, AL-ANI A, NIKOOIE R,et al. Participant retention in follow-up studies of acute respiratory failure survivors[J]. Respir Care, 2020, 65(9):1382-1391. DOI: 10.4187/respcare.07461.
|
[55] |
|
[56] |
|
[57] |
CIANI O, GRIGORE B, BLOMMESTEIN H,et al. Validity of surrogate endpoints and their impact on coverage recommendations:a retrospective analysis across international health technology assessment agencies[J]. Med Decis Making, 2021, 41(4):439-452. DOI: 10.1177/0272989X21994553.
|
[58] |
黎霞,李多多,程潞瑶,等. 中西医治疗慢性腰痛临床研究的有效率定义及其判定标准存在差异:一项概况性评价[J]. 中国全科医学,2022(20):2534-2540.
|
[59] |
任清竹,张瑞芬,苏和. 脓毒症中医证型与炎性指标及预后的相关性研究[J]. 实用中医内科杂志,2022,36(11):106-109.
|
[60] |
|
[61] |
|
[62] |
|